Welcome to our dedicated page for Abiomed news (Ticker: ABMD), a resource for investors and traders seeking the latest updates and insights on Abiomed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abiomed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abiomed's position in the market.
Abiomed, Inc. (NASDAQ: ABMD) will release its financial results for Q2 FY2021 on October 29, 2020, at 8:00 a.m. ET. The conference call, hosted by CEO Michael R. Minogue and CFO Todd Trapp, will provide insights into the company's performance. A replay will be available from 11:00 a.m. ET on October 29 to 10:00 a.m. ET on November 5, 2020. Abiomed specializes in circulatory support medical devices aimed at enhancing heart function.